Dosage protocol · Hormonal & Sexual Health
PT-141 10 mg
Typical daily range: 500–1500 mcg once daily (gradual titration over 16 weeks).
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 500–1500 mcg once daily (gradual titration over 16 weeks).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Reconstitution
PT-141 dosage chart
| Week | Dose | Draw |
|---|---|---|
| Weeks 1–8 | 500 mcg0.5 mg | 15 units0.15 mL |
| Weeks 9–12 | 1000 mcg1.0 mg | 30 units0.30 mL |
| Weeks 13–16 | 1500 mcg1.5 mg | 45 units0.45 mL |
| Draw | Draw | Dose | Draw | Draw |
|---|---|---|---|---|
| [A] | [B] | [A] × [B] | 1 / [B] | [Recon. vol. mL] × (1 / [B]) |
| [C] | [D] | [C] × [D] | 1 / [D] | [Recon. vol. mL] × (1 / [D]) |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
PT-141 is the widely used research and marketing name for bremelanotide, a synthetic peptide that acts as a melanocortin receptor agonist. In the United States it is the active ingredient in Vyleesi, a prescription drug the FDA approved in 2019 for a narrow indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.[1] That approval is specific to Vyleesi's formulation, dose, and labeled population — it does not extend to every product sold online under the "PT-141" name.
This distinction matters because bremelanotide is chemically related to earlier melanocortin research compounds studied for pigmentation and sexual response, and "PT-141" is often used loosely online to describe unregulated peptide vials marketed for broader libido or performance claims that fall outside the approved label.
Benefits & side effects
The core evidence for bremelanotide comes from two randomized, placebo-controlled Phase 3 trials, often referred to as the RECONNECT studies, in premenopausal women diagnosed with acquired, generalized HSDD.[2] Across both trials, bremelanotide produced statistically significant improvements in validated measures of sexual desire and related distress compared with placebo. It did not, however, meaningfully increase the number of satisfying sexual events — a distinction the FDA label itself highlights.
Evidence for use in men, postmenopausal women, or as a general performance enhancer is comparatively thin, resting mainly on earlier mechanistic and animal research on melanocortin agonists rather than dedicated approval-grade human trials in those populations.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.